Everyone who heard what CEO Garo said at the AGM would agree that Agenus's industry leading Next Gen CTLA4 drug (AGEN 1181) is a game changer. Garo said that the company expects this drug to be "profoundly effective". It is expected to be effective in a larger number of patients, in a larger number of indications, in a larger number of combinations, and possibly with a larger margin of safety.
That is why it is significant when Garo said that all of this could be known in as few as "20 to 30 patients". The first patient was dosed 12 weeks ago and there are now 4 sites enrolling patients. If each hospital enrolled one patient a week the enrollment right NOW could be in that 20-30 patient range!
Garo and Jenn were very jacked up during the AGM presentation. My guess is that they already know that this drug is "profoundly effective". More than that I expect that Big Pharma who want to partner also already know this because of their confidentiality agreements.
That is why it is very significant that Garo said that interest in partnering is "at an all time high" and matters are proceeding at "a very, very high pace". My guess is that AGEN 1181 will be the center-piece of multi-Billion dollar partnerships in the near future.
News 
Market Data 
Discover 
